Comparative Pharmacology
Head-to-head clinical analysis: KAINAIR versus THEOLAIR SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAINAIR versus THEOLAIR SR.
KAINAIR vs THEOLAIR-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and antagonizing adenosine receptors.
25 mg subcutaneously three times daily.
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
None Documented
None Documented
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 mL/min).
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator